Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02556346 | Withdrawn Phase 1 DMC

• 1 other identifier: MT-3724_CLL_SLL_001
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This Phase I, multiple ascending dose study will seek to enroll subjects with relapsed/refractory Chronic B-cell Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with confirmed and measurable disease who have received standard treatment with at least one anti-CD20 antibody (e.g.; rituximab, ofatumumab) containing front-line regimen that resulted in initial response, followed by relapse/recurrence and who are not eligible for any further approved biologic therapy, chemotherapy and/or autologous stem transplantation and/or refuse alternative approved therapies and/or are unlikely to achieve clinical benefit from any therapy of higher priority by Investigator assessment.

Conditions

Chronic B-cell Lymphocytic Leukemia; Small Lymphocytic Leukemia

Keywords

CD20; immunotoxin; CLL; SLL; leukemia; lymphocytic lymphoma; lymphocytic leukemia; MT-3724; relapsed; refractory; immunotherapy; cancer; antibodies; safety; pharmacokinetics

Outcome Measures

Primary Outcomes (3)

• Tolerability as measured by number of subjects with dose limiting toxicities

  Evaluation of tolerability of MT-3724 measured by number of subjects with dose limiting toxicities (DLTs)

  28 days

• Safety as measured by number of subjects with Adverse Events using CTCAE

  Safety measured by number of subjects with Adverse Events using CTCAE Version 4.03

  28 days and then every 6 months for up to 24 months following first dose if subject does not continue into Phase Ib

• Tolerability as measured by adverse events using CTCAE and clinical laboratory parameters

  Evaluation of tolerability of MT-3724 given for up to 4 additional cycles measured by number, nature and severity of Adverse Events using CTCAE Version 4.03

  2-3 weeks following last dose and then every 6 months for up to 24 months following first dose

Secondary Outcomes (5)

• PK as measured by concentrations of free MT-3724 (Cmax, Cinf)

  Days 1, 5, 8, 12, 23, and 28

• PK as measured by area under the curve of free MT-3724 (AUC)

  Days 1, 5, 8, 12, 23, and 28

• PK as measured by time to maximum concentration of free MT-3724 ( tmax)

  Days 1, 5, 8, 12, 23, and 28

• PD as measured by immunogenicity (anti-drug antibodies)

  During Screening, Days 23-25, Day 1 of cycle 2, and at final end of study visit

• Tumor Response as measured by PET or CT scan

  During Screening, Days 43 & 86

Study Arms (5)

MT-3724 Phase 1 5 mcg/kg/dose

EXPERIMENTAL

MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined

Drug: MT-3724

MT-3724 Phase 1 10 mcg/kg/dose

EXPERIMENTAL

MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined

Drug: MT-3724

MT-3724 Phase 1 20 mcg/kg/dose

EXPERIMENTAL

MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined

Drug: MT-3724

MT-3724 Phase 1 50 mcg/kg/dose

EXPERIMENTAL

MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined

Drug: MT-3724

MT-3724 Phase 1b

EXPERIMENTAL

MT-3724 IV for 6 doses over 12 days for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)

Drug: MT-3724

Interventions

MT-3724 DRUG

Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

MT-3724 Phase 1 5 mcg/kg/dose

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men or women, age 18 years or older
• Life expectancy \> 3 months
• Flow cytometric confirmation of CLL is required at screening. Previous confirmation of CLL/SLL including confirmed immunohistological diagnosis with a characteristic CD5+/CD20+ B-cell immunophenotype according to WHO criteria
• For CLL: a. An absolute peripheral blood monoclonal CD20+/CD5+ B-lymphocyte count \> 5000/μL for the duration of at least 3 months
• For SLL: An absolute peripheral blood monoclonal CD20+/CD5+ B-lymphocyte count \< 5000/μL AND Presence of lymphadenopathy and/or splenomegaly, with histopathological evaluation of a lymph node biopsy consistent with CLL/SLL.
• Staging CLL: Rai Stage III or IV disease, or stage 0-II disease that meets NCIWG criteria for active disease requiring therapy; SLL: Intermediate or high risk by Ann Arbor Staging with Cotswald Modifications that meets criteria for active disease requiring therapy.
• Relapsed/ Refractory CLL/SLL that has progressed despite treatment with all approved therapies known to provide clinical benefit for their disease and for which the potential subject is eligible or the potential subject must have refused any other available approved treatment options prior to consideration for enrollment.
• Potential subjects must have received at least one anti-CD20 antibody containing regimen in the past that resulted in initial measurable response (partial or complete remission), followed by relapse/recurrence.
• Potential subjects for which high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT) is considered a standard curative therapy are eligible for this study if the potential subject's disease has relapsed after HD-ASCT, or the potential subject is not eligible for HD-ASCT or the potential subject has refused HD-ASCT.
• Potential subjects who have had HD-ASCT must be at least 26 weeks beyond transplant.
• All potential subjects are required to have measurable disease following previous therapy for CLL/SLL. Measurable disease, as determined by NCI-WG criteria, following standard first-line or salvage therapy; this includes potential subjects with progressive disease (PDs), stable disease (SDs), or partial remission (PR) and/or Residual disease as determined by measurable disease (i.e., PDs, SDs, or PR) or by MRD positivity, determined by flow cytometry of bone marrow and/or peripheral blood (see Laboratory Manual) in potential subjects with Complete Response (CR) or CR with incomplete bone marrow recovery (CRi) (previously termed "nodular partial remission" \[(nPR\])
• Eastern Cooperative Oncology Group (ECOG) performance status of \< 2.
• Patients must be at least 28 days past their last course of leukemia or lymphoma treatment and have recovered from side effects of such therapy completely or with only minor residual symptoms including any significant laboratory. Patients with pre-existing severe or life threatening side effects/conditions from prior therapy or due to other diseases may not be enrolled
• Female patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to initiating dosing. Male and female subjects with reproductive potential must agree to use acceptable contraceptive methods while on study therapy and for 12 week following their last dose of study medication.

You may not qualify if:

• Ongoing use of any approved or investigational anti-neoplastic therapies with the exceptions of ongoing hormonal therapy for breast cancer (without evidence of active disease) or prostate cancer (stable on hormonal therapy).
• History of an absolute anti-CD20 monoclonal antibody (MAb) refractory CLL/SLL, defined as a failure to have ever achieved a PR, CR with persistent lymphocytic nodules in the marrow ("nPR"), or CR for at least 6 months in response to at least one anti-CD20 MAb-containing regimen amongst all past CLL/SLL treatments.
• Potential subjects cannot have experienced a significant (CTCAE Grade 3 or 4 with or without neutropenia) infection within 2 weeks of the first dose of MT-3724.
• Patients who cannot comply with protocol requirements including clinic visits for intravenous infusions and birth control measures may not be enrolled.
• Female patients who are pregnant or are breast feeding.
• Patients are not eligible if they are using any other approved or investigational anti-neoplastic therapies or any other investigational therapies for any other reason.
• Patients may not be receiving systemic corticosteroid therapy at a prednisone dose \> 20 mg/day (or steroid equivalent) within 2 weeks of starting study.
• Patients with uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to start of study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis may not be enrolled.
• Patients with a known history of drug abuse or any chronic neurologic, psychiatric, endocrine, metabolic, immunologic, hepatic or renal disease (including a history of hemolytic uremic syndrome) that in the opinion of the Investigator would adversely affect study participation.
• Patients with known active Hepatitis C, HIV or a present history of Hepatitis B
• Patients must not have received any vaccines for 28 days prior to administration of their first dose of MT-3724 and should not receive any vaccine during the study or within 28 days after their last dose of MT-3724.
• Patients with a suspected allergy or sensitivity to any component of MT-3724 drug preparation based upon known allergies to compounds of a similar class who have had an anaphylactic or other severe infusion reaction to human immunoglobulin or monoclonal antibody administration are not eligible.
• Potential subjects who have undergone allogeneic hematopoietic stem cell transplant or any solid organ transplant.
• Autologous hematopoietic stem cell transplant within 26 weeks prior to study entry; any history of allogeneic hematopoietic stem cell transplant.

Sponsors & Collaborators

• Molecular Templates, Inc.: lead

MeSH Terms

Conditions

Leukemia, B-Cell; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Recurrence; Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• David Valacer, MD

  Molecular Templates

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 16, 2015
• First Posted: September 22, 2015
• Study Start: November 1, 2015
• Primary Completion: August 1, 2016
• Study Completion: December 1, 2016
• Last Updated: March 2, 2016

Record last verified: 2016-02